Immunization of preterm infants with GSK's hexavalent combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine: A review of safety and immunogenicity.
CONCLUSION: GSK's hexavalent DTPa-HBV-IPV/Hib vaccine alone or co-administered with other pediatric vaccines has a clinically acceptable safety and immunogenicity profile when used in infants with history of prematurity/LBW for primary and booster vaccination. Additional studies are needed in very premature and very LBW infants. However, currently available data support using GSK's hexavalent DTPa-HBV-IPV/Hib vaccine to immunize infants with history of prematurity/LBW according to chronological age.
PMID: 29336924 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Omeñaca F, Vázquez L, Garcia-Corbeira P, Mesaros N, Hanssens L, Dolhain J, Gómez IP, Liese J, Knuf M Tags: Vaccine Source Type: research
More News: Allergy & Immunology | Cardiology | Clinical Trials | Diphtheria | Haemophilus Influenzae (Hib) | Heart | Hepatitis | Hepatitis B | Hepatitis Vaccine | HIB Vaccine | Influenza Vaccine | Men | Meningitis | Meningitis Vaccine | Pediatrics | Perinatology & Neonatology | Pneomococcal Vaccine | Respiratory Medicine | Rotavirus | Rotavirus Vaccine | Study | Tetanus | Tetanus Diptheria Pertussis Vaccine Tdap,Dtap,Dpt | Tetanus Vaccine | Vaccines | Whooping Cough (Pertussis) Vaccine